WINDLAS BIOTECH LIMITED
WINDLAS · General/Diversified · NSE
₹820
Current Market Price
Fair Value (DCF)
₹648
Discount to FV
-21.0%
Updated 32m ago
YieldIQ Score
56/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
40%
ROE
12.1%
Debt/Equity
0.06
WACC
11.1%
Market Cap
₹1,692 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.8%
Return on capital employed
EV / EBITDA
14.3×
Enterprise multiple
Debt / EBITDA
0.3×
Leverage vs earnings
Interest Coverage
19.2×
EBIT covers interest
Current Ratio
2.11×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
21.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹819.75
Bear case
Discount -110.6%
Base case
Discount -26.6%
Bull case
Discount +1.1%
Ratio Trends
WINDLAS · last 4 annual periods
ROE
12.1%
ROCE
20.8%
Operating Margin
—
Debt / Equity
0.06×
PE
11.2×
EV / EBITDA
6.8×
Historical Financials
WINDLAS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹463 Cr | ₹511 Cr | ₹629 Cr | ₹760 Cr | ₹904 Cr | +18.2% |
| EBITDA | ₹59.1 Cr | ₹70.2 Cr | ₹91.6 Cr | ₹112 Cr | ₹123 Cr | +20.0% |
| EBIT | ₹47.0 Cr | ₹57.8 Cr | ₹78.2 Cr | — | — | +13.6% |
| PAT | ₹38.1 Cr | ₹42.6 Cr | ₹58.2 Cr | ₹61.0 Cr | ₹66.5 Cr | +14.9% |
| EPS (diluted) | ₹18.80 | ₹19.70 | ₹27.88 | — | — | +10.4% |
| CFO | ₹9.1 Cr | ₹61.0 Cr | ₹109 Cr | ₹68.2 Cr | ₹105 Cr | +84.1% |
| CapEx | ₹-14.8 Cr | ₹-70.9 Cr | ₹-37.7 Cr | ₹-52.2 Cr | ₹-67.7 Cr | — |
| FCF | ₹-5.7 Cr | ₹-9.9 Cr | ₹71.3 Cr | ₹16.0 Cr | ₹37.3 Cr | — |
| Total Assets | ₹491 Cr | ₹529 Cr | ₹626 Cr | ₹760 Cr | ₹907 Cr | +16.6% |
| Total Debt | ₹6.6 Cr | ₹5.0 Cr | ₹3.6 Cr | ₹32.6 Cr | ₹35.2 Cr | +51.8% |
| Shareholders' Equity | ₹395 Cr | ₹402 Cr | ₹450 Cr | ₹506 Cr | ₹581 Cr | +10.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
WINDLAS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 INDOCO INDOCO | — | — | Pending | -10.1% | — |
 AMRUTANJAN AMRUTANJAN | — | — | Pending | 15.6% | 24.6× |
MOREPENLAB MOREPENLAB | — | — | Pending | 7.6% | — |
 HIKAL HIKAL | — | — | Pending | -4.1% | — |
SOLARA SOLARA | — | — | Pending | 0.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
4 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹18.80/sh
Last payout
2025-07-21
₹5.80
Peak payout
₹5.80
Trailing yield
0.71%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. WINDLAS BIOTECH LIMITED (WINDLAS.NS) trades at 819.75 vs a model fair value of 647.66, a gap of -21.0%. Piotroski F-score: 6/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of WINDLAS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for WINDLAS →
Compare
Head-to-head with peers
Compare WINDLAS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse WINDLASNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.